Loading clinical trials...
Loading clinical trials...
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
Conditions
Interventions
Teclistamab
Lenalidomide
Locations
211
United States
Banner University Medical Center Tucson, University of Arizona
Phoenix, Arizona, United States
UCLA Medical Center
Los Angeles, California, United States
University of California-Davis Cancer Center
Sacramento, California, United States
University of California, San Diego (UCSD) Medical Center
San Diego, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Start Date
September 8, 2022
Primary Completion Date
April 1, 2028
Completion Date
April 1, 2032
Last Updated
March 25, 2026
NCT06679101
NCT05969860
NCT06057402
NCT06383143
NCT06870760
NCT07452198
Lead Sponsor
European Myeloma Network B.V.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions